Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Welcome to the world of natural killer (NK) cell therapy, one of the emerging fields of immunotherapy. Based on the most advanced facilities of Alfa Cytology, we focus on natural killer-cell therapy, which is a breakthrough cancer therapy that utilizes the power of the immune system to combat cancer, including leukemia.
NK cells are a component of the innate immune system and can selectively recognize and kill cancer cells without prior sensitization or major histocompatibility complex (MHC) matching. They can identify abnormal cells by detecting specific markers on the surface and induce apoptosis.
NK cell therapy is a promising method for leukemia. By harnessing the power of these cells, therapeutic NK cells can be specifically activated and expanded to enhance their powerful anti-tumor response. They can directly attack cancer cells, release cytotoxic molecules, and recruit other immune cells to join the fight against tumors.
Fig. 1. Allogeneic natural killer cell therapy. (Berrien-Elliott MM.; et al., 2023)
NK cell-mediated immunotherapy enhances NK cell activation by blocking inhibitory interactions, expanding NK cell populations, and enhancing overall function. The types of NK cell immunotherapy currently being studied for leukemia include adoptive metastasis, chimeric antigen receptor-NK cells (CAR-NK), and bi-specific/tri-specific killer engagers (BiKE/TriKE).
There are many challenges in developing NK cell therapies, such as ensuring adequate expansion and persistence of NK cells in the body, optimizing their ability to specifically target cancer cells, and overcoming immunosuppressive factors in the tumor microenvironment. Therefore, Alfa Cytology accelerates NK cell therapy development, collaborating with leading research institutions, pharmaceutical companies, and healthcare organizations.
NK Cell Isolation and Expansion
Alfa Cytology supports a complete NK cell workflow, from the procurement of various cell sources (including peripheral blood or umbilical cord blood) to the isolation and amplification of NK cells.
NK Cell Optimization
Genetic modification of NK cells to improve their potency or regulate their response. Or modify NK cells to express specific cytokines or other factors, thereby improving their anti-tumor response.
NK Cell Characterization
Using flow cytometry, ELISA, microscopy, and other techniques, Alfa Cytology analyzes the phenotypic markers, cytotoxicity, and cytokine production and assesses the ability of NK cells to kill target cells.
Immune Monitoring
Employing flow cytometry and multiplex assays to monitor immune responses, and assess the impact of NK cell therapy on tumor progression and immunosuppressive mechanisms.
Professional
Technical
Platform
Extensive
Development
Experience
Highly
Sophisticated
Scientists
Preferential
Prices
Overall, natural killer cell therapy provides comprehensive support for the research and development of leukemia therapies. Alfa Cytology's natural killer cell therapy development service is designed to accelerate the translation of promising NK cell therapies from the laboratory to the clinic. Contact us immediately to explore how our R&D services can pave the way for your project.
Reference